Thanks very much for the question.
As Cathy was mentioning, ultimate access for many Canadians relies on a drug being reimbursed through either their public drug plan or a private plan. That's why the alignment with the health technology assessment is so important. As you're likely aware, agencies such as the Canadian Agency for Drugs and Technologies in Health and the Institut national d’excellence en santé et en services sociaux in Quebec are the ones that do these health technology assessments and make recommendations, largely to public plans at this time, in order for Canadians to have reimbursement.
The alignment that Cathy is talking about is really important, because at this time it could take several months before a drug is listed on a formulary, and patients will not have access until then, so we're trying to reduce that time and also align the evidence that both Health Canada and CADTH need, such that, again, when those processes are undertaken, they can happen faster.